Malignant Hypertension

Subscribe to Selected New Research on Malignant Hypertension

563 relevant articles (20 outcomes, 33 trials/studies) found for this Disease

Description: A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.

Also Known As:

Hypertension, Malignant

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 20552

Vascular Diseases: 7633

Hypertension: 76484

Malignant Hypertension: 563

Related Diseases

1.	Hypertension (High Blood Pressure)
2.	Kidney Failure (Renal Failure)
3.	Stroke (Strokes)
4.	Heart Failure
5.	Uremia

Experts

1.	Mitchell, Kenneth D: 4 articles (01/2008 - 10/2005)
2.	Mullins, John J: 4 articles (01/2008 - 10/2005)
3.	van den Born, Bert-Jan H: 3 articles (08/2008 - 08/2007)
4.	van Montfrans, Gert A: 3 articles (08/2008 - 08/2007)
5.	Patterson, Matthew E: 2 articles (01/2008 - 10/2005)
6.	Koopmans, Richard P: 2 articles (11/2007 - 08/2007)
7.	Mouton, Cynthia R: 2 articles (09/2006 - 10/2005)
8.	Immink, Rogier V: 1 article (08/2008)
9.	Hollmann, Markus W: 1 article (08/2008)
10.	van Lieshout, Johannes J: 1 article (08/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Malignant Hypertension:

1.	Antihypertensive Agents (Antihypertensives)IBA 11/01/2006 - "BACKGROUND: The incidence of malignant hypertension has declined after the introduction of antihypertensive agents. " 07/01/2003 - "RESULT: A 40 year-old man presented with episodic malignant hypertension resistant to several anti-hypertensive drugs. " 08/01/2000 - "A profound elevation of blood pressure on exercises or after withdrawal of antihypertensive drugs has been reported in patients with a history of accelerated-malignant hypertension. " 05/01/1997 - "A diagnosis of malignant hypertension was made and blood pressure was gradually controlled on oral antihypertensives. " 12/01/1995 - "1. In order to evaluate the therapeutic effects of antihypertensive agents on malignant hypertension in M-SHRSP, EEG were performed as a non-invasive, therapeutic index. " Order ALL the reference details at left...
2.	Captopril (Capoten)FDA LinkGeneric 10/01/1981 - "We conclude that captopril, alone or in combination with other drugs, is effective in both the acute and long-term management of severe and malignant hypertension." 01/01/1984 - "In four patients with various forms of malignant hypertension and impairment of renal function, GFR remained unchanged or even increased when the blood pressure was reduced by captopril. " 03/01/1983 - "We studied the changes in mean arterial pressure (MAP), cardiac index (CI), pulmonary wedge pressure (PWP), and in plasma volume (PV) induced by a single oral dose of captopril (150 mg) in 11 patients with malignant hypertension. " 03/01/1983 - "Hemodynamic mechanism of blood pressure response to captopril in human malignant hypertension." 01/01/1983 - "Captopril was used in 21 patients with various forms of stable and malignant hypertension. " Order ALL the reference details at left...
3.	CalciumIBA 07/01/1999 - "From these finding, it is concluded that combination therapy with a calcium antagonist and alphabeta-blocker is effective in both the reduction of highly elevated blood pressure and protection of the kidneys, resulting in amelioration of accelerated-malignant hypertension." 12/01/1987 - "In malignant hypertension the deleterious calcium overload in tissues may be activated or inhibited independently of the regulation of arterial blood pressure." 01/01/1986 - "Calcium and malignant hypertension in animal experiment: effects of experimental manipulation of calcium influx." 01/01/1983 - "In experimental malignant hypertension these drugs preserve tissue integrity by inhibiting the deleterious calcium overload of vessels." 01/01/1991 - "It has also been proposed that nitrendipine is able to preserve tissue integrity and increase life span in malignant hypertension, because it prevents a deleterious calcium overload in the heart and arterial vessels. " Order ALL the reference details at left...
4.	Retinaldehyde (Retinal)IBA 04/01/1991 - "The lack of improvement in the ERG record points to a permanent lesion of the retinal activity after passed malignant hypertension in spite of normalization of the arterial pressure." 01/01/2008 - "However, upon careful ocular fundus examination, detection of discrete retinal nerve fiber layer and pigment epithelial changes at a distance from the optic discs raised the probability of malignant hypertension. " 05/01/2006 - "Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension." 03/01/2006 - "Optical coherence tomography is a relatively new imaging technique for evaluating retinal thickness and the location of pathology in patients with malignant hypertension." 12/01/1993 - "Ocular complications were seen in 06% cases of malignant hypertension with variable retinal changes." Order ALL the reference details at left...
5.	DiureticsIBA 01/01/2003 - "Although useful as adjunctive therapy in hypertensive crises, diuretics should be used with caution in these patients because prior volume depletion may be present in some conditions such as malignant hypertension. " 04/01/1995 - "Clinical studies using diuretics and beta-blockers reported that thiazide treatment prevents the development of malignant hypertension, renal and heart failure, hypertensive retinopathy, and reduces in five years overall mortality of 33%, cardiovascular mortality of 41%, fatal and non-fatal cerebrovascular events of 51% and the risk of coronary events of 15%. " 06/01/1982 - " The use of diuretics, antisympathetic agents, vasodilators, and parenteral agents for malignant hypertension represents an appropriate sequence to follow in such cases." 10/01/1990 - "The drugs used in early studies - diuretics, vasodilators and reserpine - greatly improved mortality from malignant hypertension, apoplectic stroke and congestive heart failure, but had little or no effect in persons with milder degrees of elevated blood pressure, who constitute the vast majority of hypertensives. " Order ALL the reference details at left...
6.	Reserpine (Serpasil)FDA Link 05/01/1961 - "[The effect of reserpine (serpasil) on kidney function in malignant hypertension.]" 10/01/1954 - "[Effects of reserpine on chronic malignant hypertension.]" 06/20/1959 - "Mecamylamine and reserpine in the management of severe and malignant hypertension in Uganda." 10/01/1990 - "The drugs used in early studies - diuretics, vasodilators and reserpine - greatly improved mortality from malignant hypertension, apoplectic stroke and congestive heart failure, but had little or no effect in persons with milder degrees of elevated blood pressure, who constitute the vast majority of hypertensives. " Order ALL the reference details at left...
7.	Vasodilator Agents (Vasodilators)IBA 12/01/1983 - "In emergency situations with malignant hypertension more powerful vasodilators like diazoxid or Nitroprussid Sodium are necessary. " 06/01/1982 - " The use of diuretics, antisympathetic agents, vasodilators, and parenteral agents for malignant hypertension represents an appropriate sequence to follow in such cases." 10/01/1990 - "The drugs used in early studies - diuretics, vasodilators and reserpine - greatly improved mortality from malignant hypertension, apoplectic stroke and congestive heart failure, but had little or no effect in persons with milder degrees of elevated blood pressure, who constitute the vast majority of hypertensives. " Order ALL the reference details at left...
8.	CreatinineIBA 08/01/1980 - "The longest period of follow-up was five years, and one patient achieved a creatinine clearance of 23 ml/min. Renal histology, available in five cases, showed changes of malignant hypertension only, with no evidence of other renal lesions. " 10/01/1989 - "Although the pretreatment serum creatinine levels were matched, the renal function more rapidly deteriorated after development of malignant hypertension in the CGN group than did in the EHT group, indicating renal survival rate to be shorter in the former group. " 06/01/1988 - "We report on a 45 years old woman with malignant hypertension (220/135 mmHg, severe retinopathy with papilledema, progressive renal insufficiency with serum creatinine over 300 mumol/l) of recent onset. " 01/01/1988 - "(3) The hyperperfusion injury was seen as a complication of glomerulonephritis or diabetic glomerulosclerosis only when the patient clinically had developed malignant hypertension and when the serum creatinine level was elevated, a sign of compensated retention. " 09/25/1981 - "Essential arterial hypertension, malignant hypertension and renovascular hypertension were studied in 64 patients, divided into 5 groups according to creatinine clearance (Ccreat) and ophthalmic fundus. " Order ALL the reference details at left...
9.	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/01/2008 - "Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension." 10/01/2005 - "These findings indicate that superoxide anion contributes to the elevated RVR and increased arterial blood pressure, by a mechanism that is at least in part nitric oxide dependent, in Cyp1a1-Ren2 rats with malignant hypertension." 10/01/2005 - "Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension." 08/01/2000 - "Responses of blood pressure, heart rate and plasma cyclic guanosine monophosphate to intravenously infused L-arginine, a precursor of nitric oxide, was investigated in hypertensive patients with (group A) or without any history of accelerated-malignant hypertension (group B) in order to evaluate endothelial function. " 12/01/1993 - "There are three known causes for such a deficiency, (1) removal of renomedullary interstitial cells by bilateral nephrectomy, renal surgical papillectomy, chemical papillectomy, papillary atrophy or necrosis; (2) decrease in number and damage to renomedullary interstitial cells in accelerated experimental hypertension and malignant hypertension of humans; and (3) dysfunction of renomedullary interstitial cells as mediated by angiotensin II, by resetting of the effect of increased renal artery perfusion pressure, by stimulation of the renal sympathetic nerve, by inhibition of nitric oxide synthesis and possibly by inhibition of cyclo-oxygenase. " Order ALL the reference details at left...
10.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/01/1994 - "Malignant hypertension generally responds to angiotensin converting enzyme inhibitors. " 06/01/1991 - "However, the compensatory neuroendocrine activation which occurs in malignant hypertension, renal failure and congestive heart failure and concurrent diuretic therapy appears to enhance the clinical response to ACE inhibitors in African patients." 04/27/1992 - "In patients with malignant hypertension, diabetic nephropathy, and other causes of renal failure, preliminary evidence suggests that lowering the blood pressure with angiotensin-converting enzyme (ACE) inhibitors may possibly carry some other benefits compared with other blood pressure lowering regimens. " 11/01/1997 - "The frequency of malignant hypertension has decreased because of the effective treatment of essential hypertension with new antihypertensive agents: calcium antagonists, ACE inhibitors, and angiotensin II receptor antagonists. " 12/15/1992 - "Angiotensin-converting enzyme (ACE) inhibitors act by lowering the level of angiotensin II. The therapeutic benefits of these drugs and their potential side-effects therefore result from suppression of the physiological effects of angiotensin II. It is rational to prescribe an ACE inhibitor when the renin-angiotensin system is activated, as in renin-dependent essential hypertension, malignant hypertension and hypertension associated with heart failure. " Order ALL the reference details at left...

Therapies and Procedures

1.	Nephrectomy 12/19/1959 - "Malignant hypertension and hypokalaemia: cured by nephrectomy." 10/20/1956 - "Irradiation-induced malignant hypertension: cured by nephrectomy." 09/01/1956 - "Malignant hypertension in a girl of 15 relieved by nephrectomy." 07/01/1945 - "MALIGNANT HYPERTENSION CURED BY UNILATERAL NEPHRECTOMY." 07/01/1980 - "[Embolization of renal artery -- an alternative in nephrectomy in the treatment of patients with dialysis and malignant hypertension (author's transl)]" Order ALL the reference details at left...
2.	Renal Dialysis (Hemodialysis) 11/01/1980 - "Four of nine patients presenting with malignant hypertension had marked and sustained improvement in renal function, although three initially required hemodialysis. " 12/08/1979 - "Following effective long-term antihypertensive therapy, hemodialysis could be discontinued in 4 patients with malignant hypertension in view of improved renal function. " 01/01/2000 - "Clinical diagnosis of malignant hypertension was given and antihypertensive therapy and hemodialysis were immediately started. " 01/01/1999 - "In conclusion, previous malignant hypertension did not increase the risk of patients in long-term hemodialysis in our series." 01/01/1992 - "[Hemodialysis therapy of malignant hypertension]" Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 04/01/1981 - "[Effect of the resection of native kidneys in transplant recipients with malignant hypertension]" 01/01/1978 - "All cases of malignant hypertension required removal of primary kidneys, either before or after transplantation. " 04/01/1991 - "Ophthalmological examinations were carried out in 42 patients (aged 16-45 years) after kidney transplantation in whom malignant hypertension was discovered before transplantation. " 06/01/1980 - "Few therapeutic advances of proven efficacy have been forthcoming over this period except for the use of vigorous antihypertensive therapy or early nephrectomy, dialysis, and transplantation in the control of malignant hypertension and progressive renal failure." 01/01/1988 - "All patients presented a renal or renovascular disease (acute nephritis + hypoplastic dysplasia , transplantation = 58%) for which malignant hypertension was the first symptom in 16%. " Order ALL the reference details at left...
4.	Adrenalectomy 11/01/2004 - "Malignant hypertension after adrenalectomy." 01/01/1970 - "[Sympatho-adrenalectomy in essential malignant hypertension]" 01/01/1963 - "[2 CASES OF MALIGNANT HYPERTENSION TREATED WITH BILATERAL TOTAL ADRENALECTOMY.]" 12/01/1957 - "Total adrenalectomy for malignant hypertension." 01/01/1957 - "Total adrenalectomy for malignant hypertension." Order ALL the reference details at left...
5.	Nursing Care 03/27/1975 - "Nursing care study: chronic pyelonephritis with malignant hypertension." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Malignant Hypertension

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>